Other formats:
BibTeX
LaTeX
RIS
@misc{2361504, author = {Šálek, Cyril}, address = {Praha}, edition = {NA}, keywords = {blinatumomab; high-dose chemotherapy; acute lymphoblastic leukemia}, language = {eng}, location = {Praha}, publisher = {ÚHKT PRAHA}, title = {Development Safety Update Report 2023 BLINA-CELL}, url = {https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004577-14}, year = {2023} }
TY - GEN ID - 2361504 AU - Šálek, Cyril PY - 2023 TI - Development Safety Update Report 2023 BLINA-CELL VL - NA PB - ÚHKT PRAHA CY - Praha KW - blinatumomab KW - high-dose chemotherapy KW - acute lymphoblastic leukemia UR - https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004577-14 N2 - Eudra CT 2017-004577-14, Blina-Cell, NCT04554485: Single cycle of blinatumomab followed by high-dose chemotherapy in the induction therapy for Ph-negative acute lymphoblastic leukemia in adults. (Principal Investigator: doc. MUDr. Mgr. Cyril Šálek, Ph.D., cyril.salek@uhkt.cz). Single cycle of blinatumomab followed by high-dose chemotherapy in the induction therapy for Ph-negative acute lymphoblastic leukemia in adults. ER -
ŠÁLEK, Cyril. \textit{Development Safety Update Report 2023 BLINA-CELL}. NA. Praha: ÚHKT PRAHA, 2023, 14 pp. NA.
|